{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:01:37Z","timestamp":1785168097261,"version":"3.55.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008721","name":"University College London Hospitals NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["BRC4\/III\/CC"],"award-info":[{"award-number":["BRC4\/III\/CC"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.autrev.2026.104083","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:17:22Z","timestamp":1779290242000},"page":"104083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes and prognostic factors in juvenile dermatomyositis: A systematic review of studies with more than 12\u00a0months of follow-up"],"prefix":"10.1016","volume":"25","author":[{"given":"Laura","family":"Scagnellato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kostopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramonda","family":"Roberta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coziana","family":"Ciurtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.autrev.2026.104083_bb0005","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1002\/1529-0131(199910)42:10<2213::AID-ANR25>3.0.CO;2-8","volume":"42","author":"Lovell","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2026.104083_bb0010","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.200543","article-title":"Development and testing of reduced versions of the manual muscle Test-8 in juvenile dermatomyositis","volume":"48","author":"Rosina","year":"2021","journal-title":"J Rheumatol"},{"issue":"Suppl 11(011)","key":"10.1016\/j.autrev.2026.104083_bb0015","first-page":"S118","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"1","key":"10.1016\/j.autrev.2026.104083_bb0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/art.20757","article-title":"Childhood myositis assessment scale and muscle strength testing in patients with juvenile dermatomyositis: comment on the article by Huber et al","volume":"52","author":"Takken","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104083_bb0025","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/bjd.15596","article-title":"Evaluation of the reliability of the cutaneous dermatomyositis disease area and severity index and the cutaneous assessment tool-binary method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists","volume":"177","author":"Tiao","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104083_bb0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/art.23313","article-title":"Alternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: results using abbreviated formats","volume":"59","author":"Huber","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2026.104083_bb0035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104083_bb0040","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/art.1780401109","article-title":"Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group","volume":"40","author":"Rider","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104083_bb0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/art.23248","volume":"59","author":"Ruperto","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2026.104083_bb0050","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/rheumatology\/key421","article-title":"Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis","volume":"58","author":"Rosina","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2026.104083_bb0055","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104083_bb0060","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Bellutti Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2026.104083_bb0065","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1093\/rheumatology\/keaf225","article-title":"Long-term effectiveness and safety of baricitinib treatment on refractory or severe juvenile dermatomyositis","volume":"64","author":"Wang","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.autrev.2026.104083_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15960","article-title":"Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy","volume":"35","author":"Agud-Dios","year":"2022","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.autrev.2026.104083_bb0075","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104083_bb0080","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104083_bb0085","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ard.2025.02.002","article-title":"Rapid clinical and transcriptomic response to anifrolumab in refractory anti-TIF1gamma-positive juvenile dermatomyositis","volume":"84","author":"Triaille","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104083_bb0090","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/pde.16012","article-title":"Anifrolumab in refractory juvenile dermatomyositis","volume":"43","author":"Barrutia-Etxebarria","year":"2026","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104083_bb0095","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"SI2","key":"10.1016\/j.autrev.2026.104083_bb0100","doi-asserted-by":"crossref","first-page":"SI129","DOI":"10.1093\/rheumatology\/keae027","article-title":"Disease activity trajectories in juvenile dermatomyositis from childhood to adulthood","volume":"63","author":"Nozawa","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2026.104083_bb0105","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/rheumatology\/keaa497","article-title":"Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models","volume":"60","author":"Deakin","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2026.104083_bb0110","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.ard.2025.04.024","article-title":"Treating juvenile dermatomyositis to target: paediatric rheumatology European Society\/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force","volume":"84","author":"Ravelli","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"10019","key":"10.1016\/j.autrev.2026.104083_bb0115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2026.104083_bb0120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12969-019-0326-5","article-title":"The PRINTO evidence-based proposal for glucocorticoids tapering\/discontinuation in new onset juvenile dermatomyositis patients","volume":"17","author":"Giancane","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"10.1016\/j.autrev.2026.104083_bb0125","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2026.104083_bb0130","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1002\/art.30475","article-title":"Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study","volume":"63","author":"Hasija","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2026.104083_bb0135","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/acr.23840","article-title":"Association of short-term ultraviolet radiation exposure and disease severity in juvenile dermatomyositis: results from the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry","volume":"71","author":"Neely","year":"2019","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"3","key":"10.1016\/j.autrev.2026.104083_bb0140","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/rheumatology\/key342","article-title":"Cardiorespiratory fitness in long-term juvenile dermatomyositis: a controlled, cross-sectional study of active\/inactive disease","volume":"58","author":"Berntsen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2026.104083_bb0145","first-page":"535","article-title":"In juvenile dermatomyositis, heart rate variability is reduced, and associated with both cardiac dysfunction and markers of inflammation: a cross-sectional study median 13.5 years after symptom onset","volume":"55","author":"Barth","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2026.104083_bb0150","first-page":"470","article-title":"Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis","volume":"55","author":"Gitiaux","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.autrev.2026.104083_bb0155","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104083_bb0160","first-page":"117","article-title":"Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis","volume":"29","author":"Guseinova","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104083_bb0165","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/acr.20269","article-title":"Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis","volume":"62","author":"Rouster-Stevens","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104083_bb0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/acr.20015","article-title":"Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients","volume":"62","author":"Ravelli","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"10.1016\/j.autrev.2026.104083_bb0175","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/art.24904","article-title":"Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index","volume":"60","author":"Rider","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2026.104083_bb0180","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/art.24555","article-title":"Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy","volume":"60","author":"Niewold","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104083_bb0185","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MD.0b013e31816bc604","article-title":"Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity","volume":"87","author":"Bingham","year":"2008","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.autrev.2026.104083_bb0190","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/1756-185X.13759","article-title":"Long-term outcome in children with juvenile dermatomyositis: a single-center study from North India","volume":"23","author":"Sharma","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104083_bb0195","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/RHU.0000000000002127","article-title":"Prevalence and clinical implications of autoantibodies in juvenile dermatomyositis: a single-Center experience from India","volume":"30","author":"Joseph","year":"2024","journal-title":"J Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104083_bb0200","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/art.40881","article-title":"Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation","volume":"71","author":"Wienke","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104083_bb0205","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005598","article-title":"Predictors of persistent active disease and the longitudinal development of organ damage, patient-reported outcomes and autoantibodies in long-term juvenile dermatomyositis","volume":"11","author":"Berger","year":"2025","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.autrev.2026.104083_bb0210","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15379","article-title":"Incidence and outcomes for children with idiopathic inflammatory myopathy in Western Australia-a long-term population-based study","volume":"27","author":"Nossent","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104083_bb0215","first-page":"1031","article-title":"A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases","volume":"27","author":"Sato","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104083_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.abd.2025.501130","article-title":"Long-term outcome of juvenile dermatomyositis associated with lipodystrophy: experience of a university hospital","volume":"100","author":"Kapetanovic","year":"2025","journal-title":"An Bras Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104083_bb0225","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12969-025-01132-0","article-title":"Juvenile dermatomyositis in Oman: clinical patterns and disease trajectory from a national cohort","volume":"23","author":"Abdwani","year":"2025","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"10.1016\/j.autrev.2026.104083_bb0230","first-page":"379","article-title":"Longitudinal assessment of disease activity and muscle strength in juvenile dermatomyositis: a multicentre registry study","volume":"43","author":"Hortelan Antonio","year":"2025","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104083_bb0235","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12969-022-00754-y","article-title":"Juvenile dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective","volume":"20","author":"Boros","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"issue":"11","key":"10.1016\/j.autrev.2026.104083_bb0240","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1093\/rheumatology\/keab089","article-title":"Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers","volume":"60","author":"Varnier","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.autrev.2026.104083_bb0245","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s10792-021-01833-x","article-title":"Ophthalmic manifestations in patients with collagen vascular disorders: a hospital-based retrospective observational study","volume":"41","author":"Sharma","year":"2021","journal-title":"Int Ophthalmol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104083_bb0250","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1111\/jdv.70103","article-title":"Long-term outcomes of juvenile dermatomyositis","volume":"40","author":"Hladky","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104083_bb0255","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MD.0b013e31827f264d","article-title":"The clinical phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Shah","year":"2013","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.autrev.2026.104083_bb0260","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/rheumatology\/keaa497","article-title":"Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models","volume":"60","author":"Deakin","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104083_bb0265","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12969-016-0118-0","article-title":"Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study","volume":"14","author":"Okong\u2019o","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"10.1016\/j.autrev.2026.104083_bb0270","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/1756-185X.12053","article-title":"Juvenile dermatomyositis at a tertiary care hospital: is there any change in the last decade?","volume":"16","author":"Prasad","year":"2013","journal-title":"Int J Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104083_bb0275","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/rheumatology\/kep302","article-title":"Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset","volume":"48","author":"Sanner","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2026.104083_bb0280","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/08916930600622819","article-title":"National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary - clinical characteristics and disease course of 44 patients with juvenile dermatomyositis","volume":"39","author":"Constantin","year":"2006","journal-title":"Autoimmunity"},{"issue":"10","key":"10.1016\/j.autrev.2026.104083_bb0285","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/rheumatology\/kel099","article-title":"The Juvenile dermatomyositis national registry and repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr","volume":"45","author":"LJ","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2026.104083_bb0290","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00296-005-0030-2","article-title":"Twelve years experience of juvenile dermatomyositis in North India","volume":"26","author":"Singh","year":"2006","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.autrev.2026.104083_bb0295","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T","article-title":"Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis","volume":"43","author":"Huber","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104083_bb0300","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpeds.2017.01.046","article-title":"Race, income, and disease outcomes in juvenile dermatomyositis","volume":"184","author":"Phillippi","year":"2017","journal-title":"J Pediatr"},{"issue":"11","key":"10.1016\/j.autrev.2026.104083_bb0305","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/acr.21753","article-title":"Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study","volume":"64","author":"Martin","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"10.1016\/j.autrev.2026.104083_bb0310","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/ppul.22742","article-title":"The lung is involved in juvenile dermatomyositis","volume":"48","author":"Pouessel","year":"2013","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104083_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102533","article-title":"Calcinosis biomarkers in adult and juvenile dermatomyositis","volume":"19","author":"Chung","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2026.104083_bb0320","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12969-024-00999-9","article-title":"Clinical characteristics and prognostic factor in juvenile dermatomyositis: data of the Spanish registry","volume":"22","author":"Carriqu\u00ed-Arenas","year":"2024","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"10.1016\/j.autrev.2026.104083_bb0325","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3899\/jrheum.2024-0088","article-title":"Effects of juvenile idiopathic inflammatory myopathies on growth, development, and maturation: a systematic review and Metaanalysis","volume":"52","author":"Guo","year":"2025","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104083_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103284","article-title":"Subcutaneous tissue involvement in idiopathic inflammatory myopathies: systematic literature review including three new cases and hypothetical mechanisms","volume":"22","author":"Suzon","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2026.104083_bb0335","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/ar4198","article-title":"Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?","volume":"15","author":"Tansley","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104083_bb0340","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13075-018-1687-8","article-title":"Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study","volume":"20","author":"van Dijkhuizen","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.autrev.2026.104083_bb0345","article-title":"Targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies","volume":"8","author":"Raaphorst","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"10473","key":"10.1016\/j.autrev.2026.104083_bb0350","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(24)02071-3","article-title":"Efficacy, safety, and target engagement of dazukibart, an IFN\u03b2 specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Fiorentino","year":"2025","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.autrev.2026.104083_bb0355","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104083_bb0360","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10067-023-06740-3","article-title":"Biologic drugs in the treatment of juvenile dermatomyositis: a literature review","volume":"43","author":"Sener","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104083_bb0365","series-title":"Baricitinib in Juvenile Dermatomyositis (BAR-JDM): a multi-centre, open label, randomised, controlled, superiority, Bayesian, phase 3a trial comparing baricitinib and glucocorticoids to methotrexate and glucocorticoids over 52 weeks","author":"McComish","year":"2025"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:41:54Z","timestamp":1785166914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":73,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1568997226000972"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104083","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes and prognostic factors in juvenile dermatomyositis: A systematic review of studies with more than 12\u00a0months of follow-up","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104083"}}